PD-GB, SLFN11 (96-fold, p = 0.0001), acts as a negative regulator of HR [ 92 ], and that high expression of SLFN11 shows an extremely significant positive correlation with the response to TOP1/2 inhibitors, alkylating agents and DNA synthesis inhibitors in in cancer cell lines of different origin [ 93 ].
← all excerpts
Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells.
1
—
—